Open Nav
2016 Advisory Committee

Detlev Biniszkiewicz, Chief Executive Officer & President, Surface Oncology

Detlev is the President and Chief Executive Officer of Surface Oncology, Inc., a leader in the development of next-generation cancer immunotherapies that target the suppressive tumor microenvironment. In January 2016, Surface Oncology entered a global strategic collaboration to develop its novel immunotherapies.
Previously, Detlev was the Vice President of Strategy of AstraZeneca’s Oncology Unit. His group was responsible for all Oncology scientific strategy, licensing, and external academic collaborations and clinical alliances. He played key roles in setting the overall strategic direction, driving multipe licensing opportunities (>20 licensing deals), and building academic collaborations all over the world. As part of the AZ Oncology leadership, he has contributed to the successful development of Lynparza™ (PARP inhibitor olaparib) and Tagrisso™ (EGFR-mutation inhibitor AZD9291).
Detlev joined the Novartis Institutes for BioMedical Research (NIBR) as Head of Strategic Projects, leading its strategy organization. Soon after, Detlev became the Global Head of Portfolio Management at NBIR, and was responsible for the oversight and strategy of the entire portfolio of projects ranging from Target Discovery to Proof-of-Concept. Detlev also served as Principal at The Boston Consulting Group (BCG), where he led numerous projects for biotechnology and pharmaceutical companies. His Ph.D. and post-doctoral research were performed at Whitehead Institute at the Massachusetts Institute of Technology, Cambridge, MA.

Scott C. Brun, MD, Vice President, Corporate Strategy Office Head, AbbVie Ventures

Dr. Brun has worked at Abbott and subsequently AbbVie for over eighteen years in total, beginning his career as the first participant in the Abbott Physician Development Program, a mini-fellowship in pharmaceutical medicine. He has recently taken on the responsibility to lead AbbVie Ventures, where he will work closely with the Chief Strategy Officer to identify and execute on strategic venture investments that are closely aligned with AbbVie’s overall R&D and corporate strategy.

In his previous role, Dr. Brun was the head of Pharmaceutical Development at AbbVie, a 2000+ person global scientific and operational organization responsible for advancing a broad portfolio of early and late stage preregistrational pipeline compounds as well as marketed products within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health therapeutic areas. Previously, Scott was Divisional Vice President for Infectious Disease Development, where he was responsible for management oversight of multiple Global Project Teams that design and execute early and late stage clinical development programs for Abbott’s Antiviral R&D portfolios, including the marketed products Synagis for prevention of RSV infection in high risk infants, Kaletra and Norvir for the management of HIV infection, and the hepatitis C development pipeline. In the past, Dr. Brun has also directed antimicrobial, renal, and early immunology development programs at Abbott.

Dr. Brun earned his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign.  He earned his medical degree from The Johns Hopkins University School of Medicine and completed ophthalmology training at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.

Dr. Brun was part of the 2011 Donalee Tabern Outstanding Research Team at Abbott, recognized for scientific excellence in the area of hepatitis C therapeutics. Crain’s Chicago Business has recognized Dr. Brun in their “40 under 40” professional list.   Publications include over 90 abstracts and 20 manuscripts related to antiviral therapeutics.

John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners

John Chambers is the Vice-Chairman and Head of Healthcare Investment Banking group at ROTH Capital Partners. Mr. Chambers joined ROTH in December 2009. Mr. Chambers was formerly the head of Merriman Curhan Ford’s Heath Care and investment banking team. Prior to joining Merriman, he was co-head of investment banking at Rodman & Renshaw. Mr. Chambers has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. Mr. Chambers has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors.

Chambers earned his M.B.A. from Columbia Business School and his B.S. in mechanical engineering from Union College. He is based in our New York office.

Rajeev Dadoo, PhD, Partner, S.R. One, Limited

Rajeev joined SR One in 2003 and is an alum of the Kauffman Fellows Program. Rajeev has been involved with SR One’s investments in True North, Illuminoss, Avhana, Setpoint, iPierian, Cydex, Hypnion, Predix and Pinnacle.

In addition to his role at SR One, Rajeev spent time with the Competitive Excellence group within GSK working on company-wide strategic projects for GSKs Corporate Executive Team. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked at Genome Therapeutics in the business development role. Rajeev was a co-founder of Unimicro Technologies, a company that was created to develop and commercialize instrumentation for biomedical analysis.

Rajeev received his BA degree in Chemistry and Mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania, and his PhD in Chemistry from Stanford University.

David H. Donabedian, PhD, Venture Partner, Longwood Fund

Dr. Donabedian is a Venture Partner of the Longwood Fund. In his current role, David supports existing portfolio companies via BoD participation and is responsible for new company formation Dr. Donabedian led Longwood's latest investment in Millendo Therapeutics, Inc.   Dr. Donabedian joined Longwood from AbbVie (NASDAQ: ABBV) where, as Vice President & Head of Ventures and Early Stage Collaborations, he led a global team of business development and investment professionals that made minority investments in biotech companies, licensed or acquired preclinical and Phase 1 compounds and created partnerships with leading academic institutions. Prior to AbbVie, Dr. Donabedian was Senior Vice President at Locust Walk Partners a life sciences advisory firm.  Previously, Dr. Donabedian was VP Global New Deal Strategy and Development at GlaxoSmithKline (NYSE: GSK). Prior to that, he held management positions at Surface Logix and as a Senior Manager at Accenture’s Strategic Services (NYSE: ACN) Consulting Group. Dr. Donabedian began his career as a research scientist with Dow Chemical and Boston Scientific. He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held biotech company he co-founded. He is also a strategic advisor to DNATrix.

Brian Hagerty, Senior Director, Head of Healthcare Capital Markets, New York Stock Exchange

Brian Hagerty has spent the past 7 years working on Wall Street in Equity Capital Markets and Risk Management. Before joining the New York Stock Exchange, Brian spent 5 years in Equity Capital Markets at J.P. Morgan where he was responsible for the Healthcare sector, spending time both in New York City and San Francisco.  Before his time in Equity Capital Markets, Brian spent two years focused on Conflict and Risk Management, where he collaborated with cross-functional teams across both domestic and international markets to lead the analysis of high risk transactions including M&A advisories, hostile take-overs, debt/equity linked offerings, derivative transactions and other products.  Prior to joining J.P. Morgan, Brian was a Senior Financial Analyst at BAE Systems Inc, where he oversaw the financial planning behind BAE’s largest production program. 

During his time in Equity Capital Markets at J.P. Morgan, Brian executed over 40 Initial Public Offerings, 200 follow-on offerings, and a number of successful private financings.  These included landmark transactions for HCA, Quest Diagnostics, Thermo Fisher, Premier, Perrigo, SXC Health Solutions, Invitae, Juno Therapeutics and Ultragenyx.

Brian graduated with a BS in Business Economics from Brown University and holds his series 63 and 79 Licenses. Brian lives in Connecticut with his fiancé.

Charlotte Hubbert, PhD, Partner, Gates Foundation Venture Capital

Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing in innovative and technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.

Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).

Michael King, Managing Director and Senior Research Analyst, JMP Securities

Mike King is a Managing Director and senior research analyst covering the biotechnology industry.

Prior to joining JMP, Mike was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities. Beforehand, Mike served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mike has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex. Brown & Co., Hambrecht & Quist and Kidder, Peabody & Co.

In 2013, Mike ranked first among all stock pickers in the Pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal.

Mike holds a BA in finance from The Bernard M. Baruch College of the City University of New York.

Jennifer Landress, Senior Vice President and Chief Operating Officer, Biocom

Jennifer Landress, CMP, an experienced executive with more than 15 years' experience in budget management, membership, marketing and event development and execution is the Sr. VP and Chief Operating Officer for Biocom. Prior to this she held the position of Vice President of Corporate Relations.

Jennifer oversees the budget, management and goals development for the organization. Additionally, she leads the organization's marketing and events departments to identify opportunities for increased visibility for Southern California life science companies as well as the expansion of the southern California life science community. She is also responsible for Capital Development, Board management, Strategic Planning and the International initiative.

Prior to her employment at Biocom, she was Director of Operations for the Biotechnology Innovation Organization (BIO), the world's largest biotechnology organization with more than 1,200 members worldwide.

Jennifer has a Bachelor of Arts Degree in English from Bucknell University and is a Certified Meeting Professional. She resides in San Diego with her husband, Bo, and three children

Brian Leuthner, Co-Founder, President and Chief Executive Officer, Edge Therapeutics, Inc.

Brian A. Leuthner has been the Co-Founder, President and CEO of Edge Therapeutics, Inc. since its inception and also serves on the company’s board of directors. He has more than 25 years of experience in the hospital acute care marketplace, with a specific expertise in critical care and neurocritical care.

Prior to founding Edge, Mr. Leuthner was the CEO of Fontus Pharmaceuticals, the Senior Head of Marketing for The Medicines Company and the Director of Market Development for ESP Pharma. He also held marketing and sales positions of significant responsibility at Burroughs Wellcome, GlaxoWellcome and Ortho Biotech. In these leadership roles, he helped create and advance hospital business units, develop and launch new critical care products and strengthen customer relationships.

Mr. Leuthner received his B.S. and M.B.A. degrees from the University of North Carolina at Chapel Hill.

Blaine McKee, PhD, Head of Transactions and Interim Head of Corporate Development, Shire plc

Blaine joined Shire in 2014 and is Shire’s Head of Transactions and Interim Head of Corporate Development. He is also a member of the Executive Committee. Blaine was previously Chief Business Officer at 480 Biomedical, prior to which he held various roles at Genzyme Corporation and Gilead Sciences.

Michael Mirsky, Managing Director, Investment Banking, H.C. Wainwright & Co., LLC

Michael Mirsky is a Managing Director, Investment Banking at HCW. Mr. Mirsky has executed over $30 billion of financing and advisory transactions for a wide array of healthcare companies. Previously, Mr. Mirsky was a Managing Director at Rodman & Renshaw, LLC. Prior to joining the HCW Team at Rodman & Renshaw, LLC in 2008, Mr. Mirsky was an Executive Director in the Global Healthcare Investment Banking Group at UBS Securities for seven years. Mr. Mirsky holds an MBA in Finance and Management from the Leonard N. Stern School of Business at New York University and a BS in Accounting and Finance from American University. He is a Certified Public Accountant (CPA).

Carole Nuechterlein, Head, Roche Venture Fund

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. She currently serves as a director at AveXis, Lysosomal Therapeutics, and Second Genome and a board observer on Allakos and 23andMe. She also led the investments on Alios, Ambit, Ambrx, Conatus, Envoy, Nereus & Pharmasset and served as a board observer for all of these except Pharmasset. She has a BA from Valparaiso University and a JD from University of Michigan.

Julia C. Owens, PhD, President and Chief Executive Officer, Millendo Therapeutics

Dr. Julia C. Owens is the founding President & CEO of Millendo Therapeutics. She has an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Millendo in 2012, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that led to Lycera's major research partnerships with Merck & Co. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals for six years. There, she established several key partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) in business development for five years, where she led partnering for the oncology and immunology areas, as well as chaired the company's technology acquisition efforts. Dr. Owens began her business career at the University of California, San Francisco Office of Technology Management.

Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.

Sara Radcliffe, President and Chief Executive Officer, California Life Science Association (CLSA)

Sara Radcliffe was appointed the president and chief executive officer of the California Life Sciences Association (CLSA) in December 2014. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College.

Matthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb

Matthew Roden, PhD, is Vice President and Head of Strategic Corporate Development at Bristol-Myers Squibb. In this role, Matt works in close collaboration with leaders across the organization to recommend creative options and proactive strategies to expand the R&D and product portfolio. Matt also oversees the Mergers & Acquisition (M&A) team responsible for acquisitions, structured transactions and divestitures. Prior to joining BMS, Matt was a Senior Equity Analyst and head of the Biotechnology equity research team at UBS, leading coverage of large, mid, and small-cap biotechnology stocks. In this role, Matt strove to be a Street leader in clinical trial analysis, commercial ramp projections, and the regulatory and payer landscape. Earlier, Matt was a Vice President and Senior Biotech analyst at Bank of America Merrill Lynch and J.P. Morgan, the latter of which supported the Institutional Investor #2-ranked large cap biotech franchise. Matt's equity research career started in 2005 at Credit Suisse First Boston as an associate analyst covering biotechnology. Matt holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, and prior was a pre-IRTA Fellow in immuno-oncology at the National Cancer Institute. Matt also holds a M.S. degree from Georgetown University and a B.S. degree from George Mason University.

Camille D. Samuels, Partner, Venrock

Cami Samuels joined Venrock in 2014 and focuses on healthcare with an emphasis on biotech and consumer health. She currently serves on the board of Spirox, Unity, and recently stepped off the board of RegenXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade where she led investments in Achaogen (AKAO), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among others. She was also a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda). Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) where she in-licensed two of the company’s clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.

Jeremy Springhorn, Partner, Corporate Development, Flagship Ventures

Jeremy joined Flagship in 2015 and develops strategic plans for VentureLabs(r) portfolio companies, works with corporate partners, and creates innovative approaches that will lead to the firm's next breakthrough startups. Prior to joining Flagship, Jeremy was one of the original scientists at Alexion, where he played an integral role in the engineering and development of Alexion's antibody therapeutics and was one of the original inventors of the drug Soliris. He moved from research to business development, leveraging much of his drug development experience into the review of opportunities for ultra-orphan diseases. Jeremy has led or managed many of the recent deals for Alexion, worth more than $5 billion in deal value. These included the acquisitions of Enobia Pharma, Taligen Therapeutics and Orphatec as well as the partnership with Moderna Therapeutics. Along with driving business development for Alexion, he served in a key strategic role as Alexion transitioned from a development firm to a commercial stage company.

Prior to 1992, Jeremy was an Instructor of Medicine at Harvard Medical School and a postdoctoral research fellow in the Cardiovascular Division of the Department of Medicine at the Brigham and Women's Hospital. He received his Ph.D. from Louisiana State University Medical Center in New Orleans and his B.A. from Colby College. He is a member of the Licensing Executives Society and Biotechnology Industry Organization. Jeremy has also served as a member of the scientific advisory board to Arradial Inc. and currently serves as a Director of the Greater New Haven Chapter of the Juvenile Diabetes Research Foundation.

KC Stone, Managing Director, Head of Healthcare Investment Banking, BTIG, LLC

Mr. Stone is a Managing Director and Head of BTIG's Healthcare Investment Banking Group. Previously, he was Managing Director and Head of Life Science Investment Banking at Wedbush-PacGrow. Mr. Stone has a long history of working with emerging growth companies from seed-stage to publicly traded institutions, and with the investors who fund them. He led the effort to finance and provide advisory services to numerous public and private companies through his previous roles as Managing Director of the Private Placement Groups at Wedbush-PacGrow and Pacific Growth Equities. At Pacific Growth, Mr. Stone was a Senior Managing Director and Partner, and sat on the Executive and Commitment Committees. Prior to Pacific Growth, he ran the Venture Capital Services Group at Volpe Brown Whelan & Company. Mr. Stone has served on the Board of Directors of The Guardsmen, a San Francisco-based charitable organization that funds access to high-quality educational and outdoor activities for inner-city youth, and currently sits on the Board of Trustees for California Pacific Medical Center Foundation and on the Board of Governors of the Wine & Food Society of San Francisco. He graduated from the University of Colorado - Leeds School of Business.

Asish K. Xavier, PhD, Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.

Asish is based in the Johnson & Johnson California Innovation Center in Menlo Park, CA.  Asish focuses on venture investments in biotechnology and diagnostics.  Asish joined JJDC in 2004, and has led or co-led investments in over 20 biotech, diagnostics and medtech deals.

Asish previously worked in business development at BioRexis Pharmaceutical Corporation (King of Prussia, PA) which was acquired by Pfizer in 2007.  While at BioRexis, he assisted the company in raising a $30 million round of financing.  Asish has worked in business development at Structural GenomiX, Inc. (San Diego, CA), acquired by Eli Lilly in 2008; and, was a project leader at Message Pharmaceuticals, Inc. (Malvern, PA).

Asish received a Ph.D. in Chemical Engineering from the University of Houston and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors.  He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.  Asish was a postdoctoral research fellow in the Department of Chemistry at the Johns Hopkins University.